Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:37 pm Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,181,818 4.700% | 86,682 (+2.80%) | Filing History |
| 2025-02-12 09:33 am Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 5,750,000 8.420% | 1,958,580 (+51.66%) | Filing History |
| 2025-01-27 12:58 pm Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | FRANKLIN RESOURCES INC BEN | 4,137,567 6.100% | 125,519 (+3.13%) | Filing History |
| 2024-11-14 3:10 pm Purchase | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Cormorant Asset Management LP | 8,325,000 12.200% | 2,286,765 (+37.87%) | Filing History |
| 2024-11-14 1:22 pm Sale | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | T. Rowe Price Associates, Inc. | 2,492,213 4.700% | -30,491 (-1.21%) | Filing History |
| 2024-11-12 2:31 pm Unchanged | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | VANGUARD GROUP INC | 3,048,182 5.690% | 0 (Unchanged) | Filing History |
| 2024-11-12 09:33 am Sale | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 3,791,420 7.080% | -1,364,879 (-26.47%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | BlackRock Inc. BLK | 4,155,158 7.800% | 0 (Unchanged) | Filing History |
| 2024-11-07 4:27 pm Purchase | 2024-10-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | TCG Crossover GP II, LLC | 3,572,335 5.200% | 3,572,335 (New Position) | Filing History |
| 2024-11-06 08:54 am Purchase | 2024-10-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | FEDERATED HERMES INC. FHI | 3,707,364 5.440% | 3,707,364 (New Position) | Filing History |
| 2024-11-04 11:57 am Purchase | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | VANGUARD GROUP INC | 3,048,182 5.690% | 3,048,182 (New Position) | Filing History |
| 2024-10-31 12:51 pm Sale | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | FRANKLIN RESOURCES INC BEN | 4,012,048 7.500% | -628,603 (-13.55%) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | BlackRock Inc. BLK | 4,155,158 7.800% | 4,155,158 (New Position) | Filing History |
| 2024-05-01 5:08 pm Unchanged | 2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 5,156,299 9.900% | 0 (Unchanged) | Filing History |
| 2024-04-30 8:53 pm Purchase | 2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | Adage Capital Management L.P. | 5,156,299 10.350% | 5,156,299 (New Position) | Filing History |
| 2024-02-14 9:08 pm Sale | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA Capital Management, L.P. | 3,095,136 6.100% | -313,570 (-9.20%) | Filing History |
| 2024-02-14 10:02 am Purchase | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | T. Rowe Price Associates, Inc. | 2,522,704 5.600% | 2,522,704 (New Position) | Filing History |
| 2024-02-13 12:00 pm Purchase | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,774,389 9.990% | 1,363,179 (+39.96%) | Filing History |
| 2024-02-07 07:54 am Purchase | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | ADAGE CAPITAL PARTNERS GP L.L.C. | 4,466,420 9.150% | 2,516,420 (+129.05%) | Filing History |
| 2024-02-06 10:55 am Purchase | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | FRANKLIN RESOURCES INC BEN | 4,640,651 9.500% | 510,514 (+12.36%) | Filing History |